Show simple item record

dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorAksoy, Sercan
dc.contributor.authorDemirci, Umut
dc.date.accessioned2024-03-13T11:10:00Z
dc.date.available2024-03-13T11:10:00Z
dc.date.issued2023en_US
dc.identifier.citationBilici, A., Ölmez, Ö. F., Kaplan, M. A., Öksüzoğlu, B., Sezer, A., Karadurmuş, N. ... Demirci, U. (2023). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study. Acta Oncologica, 62(4), 381-390. https://dx.doi.org/10.1080/0284186X.2023.2202330en_US
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.urihttps://dx.doi.org/10.1080/0284186X.2023.2202330
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12365
dc.description.abstractAimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHER2 Protein Positiveen_US
dc.subjectBreast Canceren_US
dc.subjectNeoadjuvant Treatmenten_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectEvent-Freesurvivalen_US
dc.subjectRelapseen_US
dc.subjectReal-Wordevidenceen_US
dc.titleImpact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH studyen_US
dc.typearticleen_US
dc.relation.ispartofActa Oncologicaen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-0443-6966en_US
dc.authorid0000-0001-7934-7039en_US
dc.identifier.volume62en_US
dc.identifier.issue4en_US
dc.identifier.startpage381en_US
dc.identifier.endpage390en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1080/0284186X.2023.2202330en_US
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.identifier.wosqualityQ3en_US
dc.identifier.wos000971681800001en_US
dc.identifier.pmid37083566en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record